PLx Pharma Inc
NASDAQ:PLXP
Intrinsic Value
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. [ Read More ]
The intrinsic value of one
PLXP
stock under the Base Case scenario is
0.284
USD.
Compared to the current market price of 0.004 USD,
PLx Pharma Inc
is
Undervalued by 99%.
PLXP's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
PLXP or that its price is influenced by factors unrelated to fundamentals.
PLx Pharma Inc's market capitalization is 116.6k USD.
PLXP stock price is 0.004 USD.
PLXP stock price (0.004 USD) is 99% less than its Intrinsic Value (0.284 USD).
PLXP. Open DCF Valuation
PLXP stock price (0.004 USD) is 99% less than its Relative Value (0.284 USD). Open Relative Valuation
PLXP.
PLXP has positive Gross Profit for the last twelve months.
PLXP's ROE (Return on Equity) has increased in the last 3 years from -82% to -75%, and is approaching profitability.
PLXP's Revenue has dropped by 31% over the past 12 months.
PLXP's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -338% to -773%, and is approaching profitability.
PLXP has negative Operating Income for the last twelve months.
PLXP has negative Net Income for the last twelve months.
PLXP's ROE (Return on Equity) for the past 12 months is negative and is equal to -75%.
PLXP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -773%.
PLXP has negative Free Cash Flow for the last twelve months.
PLXP has negative three-year average ROE (Return on Equity): -210%. The company is not efficient at transforming stockholders' equity into net income.
PLXP has negative three-year average ROIC (Return on Invested Capital): -478%. The company is not efficient at using invested capital to generate operating income.
PLXP's short-term assets (30m USD) exceed its short-term liabilties (6m USD).
PLXP's long-term assets (33m USD) exceed its long-term liabilties (7m USD).
PLXP's D/E (Debt to Equity) is very low and is equal to 0.
PLXP's Altman Z-Score is very low and is equal to -12.27.
PLXP earns more than enough operating income (-64m USD) to safely cover interest payments on its debt (-490 USD).
Fundamental Analysis
PLx Pharma Inc
Balance Sheet Decomposition
PLx Pharma Inc
| Current Assets | 30.2m |
| Cash & Short-Term Investments | 25.8m |
| Receivables | 139k |
| Other Current Assets | 4.2m |
| Non-Current Assets | 3m |
| PP&E | 968k |
| Intangibles | 2.1m |
| Other Non-Current Assets | -26k |
| Current Liabilities | 6.3m |
| Accrued Liabilities | 1.2m |
| Other Current Liabilities | 5.1m |
| Non-Current Liabilities | 711k |
| Other Non-Current Liabilities | 711k |
Earnings Waterfall
PLx Pharma Inc
|
Revenue
|
4.5m
USD
|
|
Cost of Revenue
|
-4.3m
USD
|
|
Gross Profit
|
202.6k
USD
|
|
Operating Expenses
|
-64.6m
USD
|
|
Operating Income
|
-64.4m
USD
|
|
Other Expenses
|
36.8m
USD
|
|
Net Income
|
-27.6m
USD
|
Free Cash Flow Analysis
PLx Pharma Inc
What is Free Cash Flow?
PLXP Profitability Score
Profitability Due Diligence
PLx Pharma Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
PLx Pharma Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
PLXP Solvency Score
Solvency Due Diligence
PLx Pharma Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
PLx Pharma Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PLXP Price Targets Summary
PLx Pharma Inc
Ownership
PLXP Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PLXP Price
PLx Pharma Inc
| Average Annual Return | 18.91% |
| Standard Deviation of Annual Returns | 34.79% |
| Max Drawdown | -100% |
| Market Capitalization | 116.6k USD |
| Shares Outstanding | 28 603 400 |
| Percentage of Shares Shorted | 0.86% |
Company Profile
PLx Pharma Inc
Country
Industry
Market Cap
Dividend Yield
Description
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm has two commercialized products, VAZALORE 81 milligram (mg) and VAZALORE 325 mg, which are liquid-filled aspirin capsules for over the counter (OTC) distribution. The firm markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage. PLxGuard drug delivery platform employs a pH-dependent release mechanism that relies on association of lipidic excipients with APIs for targeted release in the GI tract.
You don't have any saved screeners yet
